Cantor Fitzgerald Reaffirms Overweight Rating for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 41.40% from the company’s previous close.

Several other analysts also recently weighed in on the stock. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $17.68 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.18 billion, a PE ratio of 63.14 and a beta of 0.75. The firm has a fifty day simple moving average of $16.69 and a two-hundred day simple moving average of $17.97. ADMA Biologics has a twelve month low of $5.71 and a twelve month high of $23.64.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after acquiring an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics during the third quarter valued at about $61,858,000. EWG Elevate Inc. bought a new position in shares of ADMA Biologics during the fourth quarter valued at about $480,000. Citigroup Inc. raised its stake in shares of ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.